valeant pharmaceuticals inte
(VRX:Toronto)
As of 9:30 AM 05/23/13 All times are local (Market data is delayed by at least 15 minutes).
Key Executives - valeant pharmaceuticals inte (VRX)
| Name | Board Relationships | Title | Age |
| J. Michael Pearson | 22 Relationships | Chairman and Chief Executive Officer | 52 |
| Howard Bradley Schiller | 138 Relationships | Chief Financial Officer, Principal Accounting Officer, Executive Vice President and Director | 50 |
| Susan T. Hall Ph.D. | No Relationships | Global Head of Research & Development and Senior Vice President | 52 |
| Vincent P. Ippolito | No Relationships | Senior Vice President and General Manager of Aesthetics | 53 |
| Laizer D. Kornwasser | 7 Relationships | Executive Vice President and Company Group Chairman | 41 |
Board Members - valeant pharmaceuticals inte (VRX)
| Name | Board Relationships | Primary Company | Age |
| J. Michael Pearson | 22 Relationships | Valeant Pharmaceuticals International, Inc. | 52 |
| Howard Bradley Schiller | 138 Relationships | Valeant Pharmaceuticals International, Inc. | 50 |
| H. Christian Fibiger Ph.D. | 28 Relationships | iCo Therapeutics Inc. | 69 |
| Lloyd Mitchell Segal | 32 Relationships | Thallion Pharmaceuticals, Inc. | 48 |
| Robert N. Power | 16 Relationships | Valeant Pharmaceuticals International, Inc. | 55 |
Executive Committees* - valeant pharmaceuticals inte (VRX)
| Committee Name | Chairperson | Board Relationships | Members |
| Audit Committee | Norma Ann Provencio | 71 Relationships | 3 Executives |
| Compensation Committee | Robert N. Power | 16 Relationships | 4 Executives |
| Nominating Committee | Lloyd Mitchell Segal | 32 Relationships | 3 Executives |
| Corporate Governance Committee | Lloyd Mitchell Segal | 32 Relationships | 3 Executives |
| Advisory Board | H. Christian Fibiger Ph.D. | 28 Relationships | 7 Executives |
| Finance Committee | Garrison Mason Morfit CFA | 24 Relationships | 3 Executives |
*Data is at least as current as the most recent Definitive Proxy.
| Recently Viewed | |||
| VRX:CN | C$77.13 CAD | -0.53 |  |
| Company | Last | Change |
| Actavis Inc | $128.40 USD | -1.64 |
| Allergan Inc/United States | $97.16 USD | -0.57 |
| Perrigo Co | $118.30 USD | +0.23 |
| Shire PLC | 2,123 GBp | -32.00 |
| Sun Pharmaceutical Industries Ltd | 1,006 INR | +4.10 |
| View Industry Companies | ||
Industry Analysis
VRX
Industry Average
| Valuation | VRX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 6.1x |
|
| Price/Book | 6.4x |
|
| Price/Cash Flow | 28.9x |
|
| TEV/Sales | 3.2x |
|
Post a JobJobs
- Bridgewater, NJ | Valeant Pharmaceuticals InternationalPosted: May 07
- Bridgewater, NJ | Valeant PharmaceuticalsPosted: May 21
- Bridgewater, NJ | Valeant Pharmaceuticals InternationalPosted: May 06
- Bridgewater, NJ | Valeant PharmaceuticalsPosted: May 17
Sponsored Financial Commentaries
Sponsored Links
Report Data Issue
To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Please enter your information in the following field(s):
Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
